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Oestrogens (E2) stimulate the proliferation of human breast cancer
cells predominantly via the oestrogen receptor (ER). However, the
clinical effectiveness of antioestrogens such as tamoxifen in ER+
cells is occasionally limited by intrinsic resistance or, more
commonly, the acquisition of resistance. The mechanisms under-
lying the development of anti-oestrogen insensitivity remain
elusive, particularly as it is now recognized that tamoxifen
resistance is generally not associated with the loss or abnormal
function of the ER (Encarnacion and Fuqua, 1994). An alternative
mechanism may be the progression of breast tumours to a
hormone-independent proliferative state whereby growth factors
act as the principal mitogens (Dickson et al, 1993). Of particular
interest is the insulin-like growth factor (IGF) family. IGF-1 is a
mitogen for human breast cancer cells in vitro (Lippman, 1985),
especially in the presence of E2, and acts primarily via a specific
cell surface glycoprotein receptor known as the type 1 IGF
receptor (IGF-1R; Steele-Perkins et al, 1988).
Evidence for the role of IGF-1 in breast cancer has come from
case-control studies that have reported increased circulating levels
of IGF-1 in women presenting with breast cancer (Peyrat et al,
1993). Furthermore, the expression of IGF-1R mRNA has been
found in most breast cancer cell lines and in over 90% of human
breast tumour specimens (Papa et al, 1993). Pekonen et al (1988)
have demonstrated a positive correlation between IGF-1R expres-
sion and ER and progesterone receptor (PR) content and noted an
increase in expression in malignant compared with adjacent
normal tissue. Finally, the majority of recent reports have demon-
strated that expression of the IGF-1R is vital for the inhibition of
apoptosis in tumour cells (Resnicoff et al, 1995; Dunn et al, 1997).
It is now widely postulated that IGF-1R signalling is probably
more important in the role of tumour cell survival and protection
from apoptosis than in mitogenesis (Baserga et al, 1997).
There is also mounting evidence for an interaction between the
IGF-1R and ER signalling pathways (Westley and May, 1994).
Although IGF-1 can stimulate the proliferation of E2-responsive
breast cancer cells on its own, in the presence of E2 a marked
synergistic effect is usually observed. This has been associated
with the observation that E2 can cause changes in the expression of
the IGF-1R and/or its ligands (Stewart et al, 1990; Lee and Yee,
1995). Conversely, it has been shown that IGF-1 can influence the
function of the ER. A characteristic response to E2 is the up-regu-
lation of PR expression. However, physiological concentrations of
IGF-1 were also found to increase the PR level in MCF 7 breast
cancer cells (Katzenellenbogen and Norman, 1990). This stimula-
tion was blocked by an anti-oestrogen suggesting that IGF-1 was
acting on a component of the ER pathway. In the absence of any
E2, Newton et al (1994) also observed stimulation of ER-mediated
reporter-gene activity by IGF-1 in the pituitary tumour cell line,
GH3. The mechanism of this ligand-independent activation of the
ER is still unclear but it may be involved in the development of
tamoxifen resistance.
In this study, we have evaluated the comparative effects of both
E2 and IGF-1 on cell growth in an in vitro model of intrinsic
tamoxifen-resistant, ER+ breast cancer in defined, serum-free
conditions. Our results suggest that the tamoxifen-resistance
exhibited by the MCF 7/5–23 cells (relative to the tamoxifen-
sensitive MCF 7/5–21 cells) may be associated with IGF-mediated
cell proliferation.
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Summary The relationship between oestrogen (E2) and insulin-like growth factor-one (IGF-1) was examined in both tamoxifen-sensitive
(MCF 7/5–21) and tamoxifen-resistant (MCF 7/5–23) subclones of the MCF 7 cell line. Both subclones were grown in defined, serum-free
(SF) medium over a period of 7 days with the addition of E2 or IGF-1 or a combination of both agents. Growth of both MCF 7/5–21 and 7/5–23
cells was stimulated (245% and 350%, respectively) by E2. However, only the growth of MCF 7/5–23 cells was stimulated (266%) by IGF-1. A
combination of E2 and IGF-1 significantly enhanced MCF 7/5–21 and 7/5–23 cell growth (581% and 695%, respectively). E2-induced IGF-1
receptor (IGF-1R) levels (as measured by 125I-IGF-1 binding and Northern analyses) in only MCF 7/5–23 cells. This effect was partially
inhibited by tamoxifen. In medium containing serum, the growth of only the MCF 7/5–23 cells was significantly inhibited by the IGF-1R
monoclonal antibody, aIR-3. The detection of E2-induced expression of IGF-2 using RT-PCR was demonstrated in the MCF 7/5–23 cells.
These experiments indicate that E2 may sensitize tamoxifen-resistant MCF 7/5–23 cells to the growth stimulatory actions of IGF-2 via up-
regulation of the IGF-1R and describes a cell-survival mechanism that may manifest itself as tamoxifen resistance.
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Reagents
Oestradiol and tamoxifen were purchased from Sigma Chemicals
(St Louis, MO, USA). Human recombinant IGF-1 was purchased
from GroPep (Adelaide, Australia). Oestradiol and tamoxifen
were dissolved in absolute ethanol whereas IGF-1 was dissolved
in 10 mM hydrochloric acid (HCl) with 0.1% bovine serum
albumin (BSA) (essential fatty acid-free; Sigma Chemicals). 125I-
IGF-1 (S.A: 2800 Ci mmol–1) was purchased from NEN-DuPont
(Sydney, Australia). Monoclonal antibody to IGF-1R (aIR-3) was
obtained from Oncogene Science (Cambridge, MA, USA).
Cell culture
Two cell lines were used in these studies; a tamoxifen-sensitive
(MCF 7/5–21) and a tamoxifen-resistant (MCF 7/5–23) subclone
of the parental, sensitive MCF 7 line. The tamoxifen resistance
was previously characterized as a 22-fold relative difference (Hu
et al, 1993) in the concentration of tamoxifen required to inhibit
cell growth by 50% in a growth assay performed in medium
containing serum. This characteristic phenotype was also confirmed
for the current study. Both subclones express the oestrogen-
receptor and were repeatedly found to be Mycoplasma free. Stock
cultures were maintained in Roswell Park Memorial Institute
(RPMI)-1640 (ICN Biomedicals, Aurora, OH, USA) supple-
mented with 10% fetal bovine serum (FBS: Cytosystems, Sydney,
Australia), 6 mML -glutamine (CSL, Melbourne, Australia),
0.112% NaHCO3 (ICN Biomedicals), 20 mm Hepes (CSL),
10 mg ml–1 human insulin (Actrapid HM, Novo Nordisk, Sydney,
Australia) and 20 mg ml–1 gentamicin (David Bull Laboratories,
Melbourne, Australia) at 37°C in a humidified chamber containing
5% carbon dioxide (CO2).
Cell growth assays: stock (serum-containing)
conditions
The relative tamoxifen-resistant growth of the MCF 7/5–23 cells
as compared to the tamoxifen-sensitive MCF 7/5–21 cells in stock
medium was confirmed using dose–response assays that have been
previously described (Hu et al, 1993). Cell growth experiments
were also performed in stock medium with the IGF-1R mono-
clonal antibody (mAb), aIR-3 (Kull et al, 1983). Cells were
seeded in 12-well plates (Costar) at a concentration of 1 ´ 104
cells/well in 1 ml of stock medium. Forty-eight hours later, fresh
stock medium containing aIR-3 (1 mg ml–1) or vehicle (1 mg ml–1
mouse IgG1) was added and the cells were further incubated for
5 days. The rate of cell proliferation was determined by using the
MTT colorimetric cell growth assay kit (Sigma Chemicals)
according to the manufacturer’s specifications which involved
spectrophotometric measurement of cell growth as a function of
the mitochondrial activity of living cells.
Serum-free conditions
A week before each experiment, cells were withdrawn from
endogenous steroids present in FBS as originally described by
Musgrove and Sutherland (1993). Stock cell cultures were
passaged into phenol red-free RPMI-1640 (Gibco-BRL, Grand
Island, NY, USA) containing all the supplements described above
with the exception of FBS which was substituted with 10%
dextran–charcoal-treated FBS (DCC medium; Darbre et al, 1983).
The DCC medium was replenished twice over the next 5–7 days
by which time cells had reached exponential growth phase and
were ready for experimental use.
To assess the effect of E2 or IGF-1, as well as E2 in combination
with IGF-1, on growth rates, cells were seeded in 6-well plates
(Costar, Cambridge, MA, USA) at an initial concentration of
1 ´ 105 cells/well in 2 ml of DCC–FBS medium. Twenty-four
hours later, the medium was changed to 5 ml of serum-free, phenol
red-free RPMI-1640 supplemented with transferrin (30 nM;
Boehringer, Mannheim, Germany), 6 mML -glutamine, 0.112%
NaHCO3, 20 mM Hepes and 20 mg ml–1 gentamicin (SF medium)
and 10 mg ml–1 human insulin. A further 24 h later, SF medium
without insulin but containing 1.0 nM of IGF-1, E2 or combina-
tions thereof or equivalent volumes of vehicle solvent were added
to the cells as stated in the figure legends. Cell numbers were
determined daily after the cells were harvested with a 0.05%
trypsin (CSL) and 0.02% EDTA (Flow) solution and viable cells
(based on trypan blue dye exclusion) counted using a haemo-
cytometer. All experiments were performed in triplicate and were
repeated at least once. Results obtained at the varying concentra-
tions of each mitogen were expressed as a percentage of vehicle
control, the mean ± standard error of the mean (SEM).
IGF-1 binding assays
To determine the role of E2 in up-regulating the IGF-1R, 125I-IGF-
1 binding was measured in monolayers of MCF 7/5–21 and MCF
7/5–23 cells that had been progressively withdrawn from medium
containing serum in an identical manner as for the cell growth
assays. Prior to the binding assay, the cells were seeded into
25 cm2 culture flasks (Corning Inc., Corning, NY, USA) in DCC
medium at a density of 106 cells/flask. After allowing 24 h for cell
attachment, the medium was changed to SF medium with insulin.
Twenty-four hours later, cells were washed once with sterile phos-
phate-buffered suline (PBS) and incubated in SF medium
containing vehicle, E2, tamoxifen or a combination of E2 and
tamoxifen, as stated in the figure legends. Cells were incubated (in
quadruplicate) with these reagents for a period of 3–5 days. The
monolayers were then washed once with binding assay buffer;
sterile PBS containing 0.1% essential fatty acid-free BSA and
incubated with 10–15 pM 125I-IGF-1 in 5 ml of binding assay
buffer for up to 16 h at 4°C.
Non-specific binding was determined by incubating cells with
125I-IGF-1 in the presence of 100 nM unlabelled IGF-1 and 50 mM
insulin and was typically 10–20% of total bound radioactivity.
Specific binding in the presence of either aIR-3 (10 mg ml–1) or
insulin (50 mM) was also determined to estimate the proportion of
total 125I-IGF-1 binding to the IGF-1R or to IGF binding proteins
(IGFBP). These experiments utilized the distinctive binding prop-
erties of the aIR-3 antibody and insulin, both of which will effec-
tively compete for binding with 125I-IGF-1 to the IGF-1R at high
concentrations but not to the IGFBP (Jones and Clemmons, 1995).
After the incubation period, the cells were washed three times
with ice-cold binding assay buffer and solubilized with a 0.1%
Triton X100, 0.5 M NaOH solution for subsequent determination
of bound radioligand using a gamma counter (Cobra-II, Packard,
Meriden, CT, USA) with an efficiency of 81% for detecting the 125I
isotope. The statistical significance of the data was established
using the analysis of variance method followed by Fisher’s multi-
comparison test.
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Total RNA was isolated by acid guanidium thiocyanate/phenol-
chloroform extraction (Chomczynski and Sacchi, 1987) of cells
that were incubated with test reagents after a week of steroid depri-
vation as described above. All RNA concentrations were deter-
mined spectrophotometrically and the integrity of the RNA was
visualized by electrophoretical separation on 1.25% agarose (IBI,
New Haven, CT, USA)/2.2 M formaldehyde denaturing gels. RNA
was transferred to nylon membranes (MSI, Westboro, MA, USA)
by capillary action, UV fixed and stored at –20°C. Human (h)-
IGF-1, h-IGF-2 or rat-IGF-1R cDNA probes (generous gifts from
Dr Kay Lund) or 18S ribosomal RNA probes (Bresatec, Adelaide,
Australia) were labelled using a-32P-dCTP (NEN-DuPont) by
random priming and hybridization was performed in a 50%
formamide, 5 ´ SSPE [0.75 M potassium chloride (NaCl), 50 mM
NaH2PO4·H2O, 5 mM EDTA], 0.5% sodium dodecyl sulphate
(SDS), 0.35 mg ml–1 herring sperm DNA and 5 ´ Denhardt’s solu-
tion at 42°C for approximately 16 h. Blots were then washed in a
2 ´ SSC (0.3 M NaCl, 0.03 M Na3citrate)/0.1% SDS solution for
10 min at 42°C, 1 ´ SSC/0.1% SDS for 15 min at 42°C and finally
in 0.1 ´ SSC/0.1% SDS for 30 min at 55°C. Blots were exposed to
X-ray film (NEN-DuPont) with intensifying screens at –70°C for
3–10 days. Quantification of radiolabelled bands was performed
with the Instant Imager system (Packard, Meriden, CT, USA).
RT-PCR analysis
Poly (A)+ RNA was isolated using the Quickprep Micro mRNA
purification kit (Amrad Pharmacia, Sydney, Australia) from cells
that were incubated with the reagents indicated in the figure
legends under SF conditions. For cDNA synthesis, no more than
100 ng of poly (A)+ RNA was added to 100 ng of random hexa-
mers and double-distilled water (DDW) to a reaction volume of
10 ml. The mixture was incubated at 70°C for 5 min, chilled on ice
for 2 min, followed by the addition of 10 ml of the cDNA synthesis
master-mix such that the final reactions contained 50 mM Tris-HCl
(pH 8.3), 1 mM each of dATP, dGTP, dCTP and dTTP (dNTP),
75 mM KCl, 3 mM magnesium chloride (MgCl2), 5 mM dithio-
threitol, 200 units of M-MLV reverse transcriptase (RT) (Gibco-
BRL) and 10 units of RNase inhibitor (Gibco-BRL). The reaction
mix was incubated at 37°C for 60 min, diluted with 30 ml of DDW
and terminated by a final 5 min incubation at 90°C.
Both IGF-2 and histone 3.3 (H3.3) mRNA expression were
assayed by semi-quantitative reverse transcriptase polymerase
chain reaction (RT-PCR) using specific primers for amplification.
The IGF-2 primers were sense GGCTTCTACTTCAGCAGGC
(exon 6) and antisense GTGGGTAGAGCAATCAGGG (exon 8)
yielding a 344 bp product. The H3.3 primers were sense CCACT-
GAACTTCTGATTCGC (exon 2) and antisense GCGTGC-
TAGCTGGATGTCTT (exon 3) yielding a 214 bp product. The
ubitiquously expressed H3.3 gene was used as an endogenous
internal control for IGF-2 in the RT-PCR assay to check RNA
integrity and loading. For IGF-2 detection, one-tenth of the reac-
tion volume obtained after cDNA synthesis (5 ml) was diluted with
a PCR-mixture (up to a final volume of 50 ml) such that the final
reaction consisted of 0.5 mM each of the primer pair, 20 mM Tris-
HCl (pH 8.3), 50 mM KCl, 0.1 mg ml–1 BSA, 1.5 mM MgCl2,
0.2 mM of each dNTP and 1.0 unit of Taq polymerase (Promega,
Sydney, Australia). The PCR mixture was overlaid with 50 ml of
mineral oil (Sigma) to prevent evaporation and then underwent a
thermal cycling protocol consisting of 35 cycles of template denat-
uration at 95°C for 1 min, primer-template annealing at 57°C for
1 min and polymerase extension at 72°C for 1 min, followed by a
final extension at 72°C for 10 min on an Omnigene thermal cycler
(Hybaid, Melbourne, Australia).
The H3.3 gene was always assayed simultaneously using the
identical protocol as described above for the IGF-2 gene with the
only exception being that the cDNA template was diluted 1:10
before PCR cycling due to the relatively high abundance of H3.3
expression compared to IGF-2. The PCR cycling parameters were
determined from preliminary experiments where we demonstrated
that amplification of both IGF-2 and H3.3 levels was in the
exponential phase of PCR at 35 cycles for the concentrations of
template that were used. Thus, levels of IGF-2 expression detected
by RT-PCR were normalized for levels of H3.3 for every sample
and comparisons of the IGF-2/H3.3 ratios between samples were
made only within the same assay. The negative cDNA template
control (DDW) was subjected to 40 cycles of PCR with no ampli-
fication of H3.3 or IGF-2 detected. Quantification of IGF-2 and
H3.3 levels were performed using Molecular Analyst software on
a UV-Gel-Documentation instrument (BioRad, Sydney, Australia)
analysing the PCR product signal after size-fractionation on a
1.5% agarose gel.
RESULTS
Tamoxifen-sensitive and resistant breast cancer cells
are E2-responsive but differ in IGF-1 sensitivity
In the presence of tamoxifen, the proliferation of both MCF 7
subclones was significantly altered over a time-course of 7 days. In
dose–response growth assays, the concentrations of tamoxifen that
resulted in a 50% inhibition of cell growth (IC50) were 66.1 nM and
1.08 mM in the MCF 7/5–21 and 7/5–23 subclones (Figure 1),
respectively. This represented a 17-fold difference in sensitivity to
tamoxifen, results that were similar to our earlier studies (Hu et al,
1993) which also demonstrated that the ER number and affinity
of binding to E2 was not different between the two cell lines
(Parisot et al, 1995).
Both subclones were successfully cultured in defined, serum-
free conditions after approximately a week of serum withdrawal.
Under these conditions, the response to the mitogens E2 and IGF-1
could be determined with negligible interference from residual E2
and/or growth factors normally present in serum. By day 7 of cell
culture, the growth of the tamoxifen-sensitive, MCF 7/5–21 cells
was stimulated 2.5-fold by E2 (compared to vehicle controls) at a
physiological concentration of 1 nM (Table 1). The ethanol vehicle
had a minimal effect on cell growth (data not shown). By itself,
IGF-1 (1 nM) had no effect on the growth of these cells compared
to vehicle controls; however, the combination of E2 and IGF-1
markedly enhanced cell growth almost sixfold.
The growth of MCF 7/5–23 cells was stimulated 3.5-fold by E2
by day 7 of the experiment. When E2 and IGF-1 were combined,
enhanced proliferation of MCF 7/5–23 cells was also demon-
strated (almost sevenfold) compared with either agent alone
(Table 1). In contrast to MCF 7/5–21 cells, IGF-1 alone enhanced
the growth of MCF 7/5–23 cells to levels similar to those attained
with E2. A more detailed investigation of the response of both
MCF 7/5–21 and MCF 7/5–23 cells to different doses of IGF-1 (up
to 100 nM) over a 7-day period demonstrated that only the prolifer-
ation of the tamoxifen-resistant, MCF 7/5–23 cells increased in a
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had only a slight inhibitory effect on the IGF-1-mediated growth
of MCF 7/5–23 cells (data not shown).
E2 up-regulates IGF-1 binding in tamoxifen-resistant
but not in tamoxifen-sensitive breast cancer cells
To determine whether the enhanced stimulatory effect of the
combination of E2 and IGF-1 on the growth of both MCF 7/5–23
cells and MCF 7/5–21 cells could be attributed to an alteration in
the expression of the IGF-1R by E2, we measured the effects of E2,
tamoxifen alone and E2 plus tamoxifen on 125I-IGF-1 binding. A
twofold increase in the specific binding of 125I-IGF-1 was demon-
strated in the MCF 7/5–23 cell line after exposure to 1 nM E2
(Figure 2A). A similar effect was not observed in the MCF 7/5–21
cell line (Figure 2A). Whereas, tamoxifen alone had no effect on
the level of 125I-IGF-1 binding in either cell line, this antioestrogen
was able to partially inhibit the effect of 1 nM E2 on the binding of
125I-IGF-1 in the MCF 7/5–23 cell line (Figure 2A), suggesting
that the increase in binding was mediated via the ER. Specific 125I-
IGF-1 binding measured in the presence of either aIR-3 or insulin,
both of which do not bind to IGFBP, demonstrated that after treat-
ment with E2 the increase in 125I-IGF-1 in MCF 7/5–23 cells was
predominantly to the IGF-1R (Figure 2B). Again, this effect of E2
on  125I-IGF-1 binding to the IGF-1R was not observed with the
MCF 7/5–21 cell line (data not shown).
Northern blot analysis detects the up-regulation of IGF-
1R gene expression by E2 in tamoxifen-resistant breast
cancer cells
To examine whether the effects of E2 on 125I-IGF-1 binding corre-
lated with an effect on the expression of IGF-1R mRNA, we
carried out Northern blot analyses of total RNA isolated from
MCF 7/5–21 and 7/5–23 cells as described in the Materials and
methods. The hybridization of the IGF-1R probe to both the 11 and
7 kilobase mRNA transcripts described in human tissues (Ullrich
et al, 1986) is evident in MCF 7/5–23 cells as illustrated in Figure
3. The rat IGF-1R cDNA probe was used to detect hIGF-IR
mRNA in these cell lines as it shares 94% sequence homology to
its human counterpart (Werner et al, 1989). In the tamoxifen-resis-
tant MCF 7/5–23 cells, 4–24 h of exposure to 1 nM E2 in SF
medium resulted in a rapid induction of IGF-1R mRNA expression
(Figure 3). This effect was still evident when expression of IGF-1R
mRNA was measured after 120 h of E2 exposure (Figure 3) but
was not as marked as in the shorter time course. No effect of E2 in
the tamoxifen-sensitive MCF 7/5–21 cells was observed at any
time period (data not shown). When the MCF 7/5–23 cells were
incubated with E2 and tamoxifen simultaneously for 120 h, the
induction of the IGF-1R mRNA was moderately inhibited (Figure
3), a result which correlated with data from the IGF-1 binding
assays over the same time-course. The effect of tamoxifen alone
on IGF-1R mRNA levels in MCF 7/5–23 cells was not signifi-
cantly different from vehicle controls overall (three experiments).
RT-PCR analysis detects IGF-2 mRNA induced by E2 in
both breast cancer cell lines but no IGF-1 gene
expression
Northern data analysis revealed no IGF-1 or IGF-2 mRNA in
either cell line grown in SF conditions (data not shown). However,
the highly sensitive RT-PCR technique was able to detect IGF-2
expression in both the MCF 7/5–21 cells and the MCF 7/5–23
cells when both cell lines were incubated with vehicle (0.1%
ethanol) in SF medium (Figure 4). Relative to the corresponding
H3.3 levels for each sample, the basal expression of IGF-2 was
increased by 5 days of E2 exposure in both the MCF 7/5–21 cells
(161 ± 4%) and the MCF 7/5–23 cells (240 ± 42%). Co-incubation
of both cell lines with E2 and tamoxifen reduced the expression of
IGF-2 to near basal levels. Under no condition did we detect the
expression of IGF-1 mRNA in either cell line using RT-PCR (data
not shown).
aIR-3 inhibits the growth of only tamoxifen-resistant
breast cancer cells
Experiments measuring the effect of the IGF-1R mAb, aIR-3, on
the rate of cell proliferation in stock medium demonstrated that
whereas the antibody had no significant effect on MCF 7/5–21 cell
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Table 1 Effect of E2, IGF-1 or a combination of both agents on MCF 7/5–21
and MCF 7/5–23 cell proliferation
Cell line E2 IGF-1 E2 + IGF-1
MCF 7/5–21a 245 ± 27b 119 ± 7 581 ± 26b
MCF 7/5–23a 350 ± 51b 266 ± 19b 695 ± 82b
Cells were plated in 6-well plates after being withdrawn from oestrogens as
described in Materials and Methods. Triplicate wells were then treated for
7 days with SF medium supplemented with either vehicle (0.1% ethanol), E2
(10–9 M), IGF-1 (10–9 M) or a combination of E2 + IGF-1 (10–9 M). Cell numbers
were measured and results were expressed as a % of the number of viable
cells counted in the absence of any drug (vehicle only), with each number
representing the mean ± SEM of three separate experiments. aExpressed as
a % of vehicle control. bP < 0.05 by ANOVA and Fisher’s multi-comparison
statistical significance tests.
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Figure 1 The effect of tamoxifen on MCF 7/5–21 and 7/5–23 cell
proliferation. Cells from both subclones were seeded in stock medium and
allowed to reach the exponential growth phase (48 h). The subclones were
incubated with stock medium supplemented with either vehicle (0.1%
ethanol) or a range of tamoxifen concentrations (10–8–10–5 M) for a further
5 days as described in Materials and methods. Results are expressed as a
% of the number of viable cells counted in the absence of any drug (vehicle
only) with each bar representing the mean ± SEM of three separate
experiments, each performed in triplicategrowth (Figure 5), significant growth inhibitory effects were
demonstrated in the MCF 7/5–23 cells. The MTT assay was
employed in these experiments as a measurement of the antibody’s
effect on actively dividing cells as opposed to counting the number
of viable cells.
DISCUSSION
We have previously demonstrated that compared to its sister
subclone MCF 7/5–21, the relative tamoxifen resistance of the
MCF 7/5–23 cells was not explained by the loss of expression of
the ER or by a lower affinity of the ER for tamoxifen (Parisot et al,
1995). Thus we reasoned that the tamoxifen-resistant phenotype
may have been due to the E2-independent, autonomous growth of
MCF 7/5–23 cells. In order to test this hypothesis and examine the
role of mitogens such as E2 and IGF-1, we measured the growth of
cells in defined, serum-free conditions to avoid potential contami-
nation by residual E2 or other growth factors present in charcoal-
stripped FBS. In growth assays completed over a period of 7 days,
we were able to demonstrate a proliferative response to E2 (in the
absence of insulin) in both the MCF 7/5–21 and MCF 7/5–23
subclones. In this study, IGF-1 alone was not mitogenic in the
MCF 7/5–21 cells but was significantly mitogenic in the MCF
7/5–23 cells (Table 1).
With the exception of earlier studies by Huff et al (1986) and
Karey and Sirbasku (1988), more recent data have shown that IGF-
1 alone has only a slight effect on MCF 7 cell proliferation. The
larger effects of IGF-1 in these earlier studies were most likely due
to the low levels of residual E2 in the culture medium or the pres-
ence of the phenol-red dye, a weak E2 (Berthois et al, 1986). Hence,
studies which used a more severe E2-withdrawal regimen lasting
almost a week, as well as phenol-red free medium, observed very
small effects of IGF-1 on MCF 7 cell proliferation (Stewart et al,
1990, 1992; Thorsen et al, 1992; Wiseman et al, 1993). However,
all of these studies were able to demonstrate a marked synergistic
effect of E2 and IGF-1 on MCF 7 cell proliferation despite the
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Figure 2 The effect of E2 and tamoxifen on IGF-1 binding to breast cancer
cells in serum-free conditions. After the cells were withdrawn from oestrogens
as described in Materials and methods, binding of 125I-IGF-1 was measured
after 5 days incubation in SF medium with the following additions: vehicle
(0.1% ethanol), E2 (10–9 M), E2 (10–9 M) + tamoxifen (10–6 M) and tamoxifen
(10–6 M). Near-confluent monolayers of MCF 7/5–21 and 7/5–23 cells were
incubated for 16 h at 4°C with 10–20 pM of 125I-IGF-1 ± 100 nM IGF-1 and
50 mM insulin to determine specific, total binding (A) or plus aIR-3 (10 mg ml–1)
or insulin (50 mM) to determine specific binding to the IGF-1R or IGFBP
components in the MCF 7/5–23 cell line (B). The cells were washed, lysed
and radioactivity counted. Results are expressed as a % of the vehicle control
values and are normalized for cell protein content. Each bar represents the
mean ± SEM of six separate experiments with a significant (P < 0.05)
difference in IGF-1 binding for the group E2 vs EtOH in MCF 7/5–23 cells only
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Figure 3 Northern blot analyses of IGF-1R mRNA expression in MCF
7/5–23 cells. Total RNA was extracted from cells withdrawn from oestrogens
and treated in SF medium for 0–120 h with the following additions as
indicated: vehicle (0.1% ethanol), E2 (10–9 M), tamoxifen (10–6 M) and E2
(10–9 M) + tamoxifen (10–6 M). At least 30 mg of total RNA was size-
fractionated by gel electrophoresis, transferred to a nylon filter, hybridized
with the a- 32P-dCTP-rIGF-1R cDNA probe, autoradiographed for up to
10 days and quantified by image analysis. Results from the representative
experiment are expressed as a % of the vehicle control and have been
corrected for loading by normalizing for 18S ribosomal RNA levels. Similar
results were observed in repeated experimentsinsignificant effect of IGF-1 alone, as was observed in this study
with the MCF 7/5–21 cells.
This synergy between E2 and IGF-1 on ER+ breast cancer cell
proliferation has been previously attributed to the up-regulation of
the IGF-1R by E2 (Stewart et al, 1990; Westley and May, 1994;
Huynh et al, 1996; Clarke et al, 1997). Similarly, our results
demonstrated that the addition of E2 doubled 125I-IGF-1 binding in
the tamoxifen-resistant MCF 7/5–23 cells over a 5-day period.
That the E2-induced increase in 125I-IGF-1 binding in MCF 7/5–23
cells was due to the induction of IGF-1R mRNA by E2 was
confirmed using Northern blot analyses. It was found that E2 expo-
sure for 24 h increased the expression of IGF-1R mRNA about
threefold in MCF 7/5–23 cells and was still relatively elevated 4
days later, data which correlated with the results of the binding
assay. Yet, peculiarly, we were unable to demonstrate this effect in
the tamoxifen-sensitive MCF 7/5–21 cells.
The role of the IGFBP cannot be discounted as it may mask
changes in the level of the IGF-1R in the MCF 7/5–21 cells when
measured by 125I-IGF-1 binding assays. However, preliminary exam-
ination of specific 125I-IGF-1 binding to the IGF-1R by using the
aIR-3 antibody or a high concentration of insulin revealed that there
was no effect of E2 in the MCF 7/5–21 cells but 125I-IGF-1 binding to
the IGF-1R was still increased in the MCF 7/5–23 cells. Hence, the
induction of 125I-IGF-1 binding was most probably indicative of an
increment in IGF-1R number and not a measurement of membrane-
associated IGFBP activity. Nevertheless, we did observe that up to
80% of specific 125I-IGF-1 binding in these MCF 7 subclones was to
the IGFBP as has been previously reported (Kleinman et al, 1995).
The data also demonstrate that IGF-1R signalling is activated
during the culture of either of the subclones in serum-containing
medium because of the ability of the IGF-1R mAb, aIR-3, to
inhibit the growth of the cells. Although the inhibition of MCF
7/5–21 cell growth by aIR-3 was not significant, the mean level of
cell growth inhibition was 20%, a range comparable to that
observed with the MCF 7 cells at a concentration of 1 mg ml–1 anti-
body (Rohlik et al, 1987; Arteaga and Osborne, 1989). In contrast,
aIR-3 (1 mg ml–1) significantly inhibited the growth of the MCF
7/5–23 cells by 50%, implicating a higher level of IGF-1R activity
in this cell line.
Although others have reported over-expression of the IGF-1R in
breast cancer (Pekonen et al, 1988; Papa et al, 1993) there are only
limited data regarding the association of this finding with the
development of tamoxifen resistance in ER+ breast cancer
(Wiseman et al, 1993). Decupis et al (1995) observed that,
although E2 increased the number of IGF-1R in tamoxifen-resis-
tant MCF 7/LCC2 cells, it did not do likewise in tamoxifen-resis-
tant MCF 7/LY-2 cells. Similarly, van den Berg et al (1996)
observed that E2 failed to up-regulate the IGF-1R in the tamoxifen-
resistant ZR-75-9al cells, which expressed a lower level of the
IGF-1R (McCotter et al, 1996). This difference between the
tamoxifen-resistant cell lines is presumably related to the level of
expression of the ER and the degree of E2 responsiveness.
Wiseman et al (1993) suggested that the development of tamox-
ifen resistance occurred via the agonistic (oestrogenic) properties of
tamoxifen increasing the expression of the IGF-1R. They reported an
increase in 125I-IGF-1 binding by tamoxifen in a tamoxifen-resistant
subclone of MCF 7 cells. In contrast, I detected no agonistic effects
of tamoxifen in the MCF 7/5–23 cells. However, our data indicated
that tamoxifen was unable to completely inhibit E2-induced 125I-IGF-
1 binding to basal levels. When tamoxifen was co-incubated with E2,
the resultant 125I-IGF-1 binding was partially inhibited compared
with E2 alone (Figure 2A) and tamoxifen partially inhibited E2-
induced IGF-1R mRNA expression (Figure 3), suggesting that
tamoxifen was predominantly acting as an E2 antagonist in these
cells and under these conditions but was not fully effective.
A possible explanation for the difference in these observations
may be the methods used to generate these tamoxifen-resistant cell
lines. Although the results of Wiseman et al (1993) were obtained
with subclones selected in the continued presence of tamoxifen,
the tamoxifen-resistant MCF 7/5–23 cell line reported herein
represented a spontaneously generated subclone obtained by main-
taining the genetically unstable MCF 7 cells in continuous expo-
nential growth (Reddel et al, 1988). No other selective pressure
was used to achieve tamoxifen resistance (defined relative to its
sister subclone MCF 7/5–21, generated concurrently).
Many investigators have shown an increase in 125I-IGF-1
binding or IGF-1R mRNA after E2 treatment in the MCF 7 cell
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Figure 4 RT-PCR analysis of IGF-II and H3.3 mRNA expression. Poly (A)+
RNA was reverse-transcribed and one-tenth of the reaction volume was
amplified with specific primers for IGF-2 and histone 3.3 for 35 cycles.
Following PCR, the amplified products were electrophoresed in 1.5%
agarose gels stained with ethidium bromide (0.5 mg ml) and the fluorescence
quantified with image analysis software. Legend: pBR322/Msp1 Mw ladder
(lane 1); DDW (lane 2, 9), MCF 7/5–21 cells and MCF 7/5–23 cells incubated
with vehicle (0.1% ethanol), E2 (10–9 M) and E2 (10–9 M) + tamoxifen (10–6 M),
respectively, with amplification for IGF-2 (5–21: lanes 3–5; 5–23: lanes 6–8)
and histone 3.3 (5–21: lanes 10–12; 5–23: lanes 13–15). Data from this
representative experiment was similar to those observed in repeated
experiments.
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Figure 5 Inhibition of cell growth by the IGF-1R monoclonal antibody (aIR-
3). MCF 7/5–21 and 7/5–23 cells were plated and grown for 48 h in RPMI-
1640 with 10% FBS before the addition of aIR-3 (1 mg ml–1). Five days later,
the rate of cell proliferation was determined by spectrophotometric
measurement of MTT dye reduction. Results are expressed as a % of the
absorbance measured in the presence of vehicle only (1 mg ml–1 mouse IgG1)
with each bar representing the mean ± SEM of two separate experiments
with a significant (P < 0.05) difference for MCF 7/5–23 cells only.line (Freiss et al, 1990; Stewart et al, 1990; Decupis et al, 1995;
Huynh et al, 1996; Clarke et al, 1997). It is unclear to us why E2
failed to increase 125I-IGF-1 binding or IGF-1R mRNA levels in
the MCF 7/5–21 cells, given that their rate of proliferation was
also increased synergistically by co-incubation with E2 and IGF-
1. Another possible explanation could be that the synergy
between E2 and IGF-1 is also dependent on other mechanisms
besides the up-regulation of the IGF-1R by E2. Recently, it has
been proposed that the synergy between E2 and IGF-1 may be
mediated by increased activation of the ER through IGF-1R
cross-talk. Stimulation of the IGF-1R has been implicated in the
increase of ER-phosphorylation through the Ras-MAPK cascade
of the IGF-1R signalling pathway (Kato et al, 1995) resulting in
enhanced ER-mediated cell proliferation.
The detection of IGF-1R mRNA expression in the MCF 7/5–23
cells and their sensitivity to IGF-1 lead us to question whether the
IGF-mediated proliferation of these cells was via an autocrine
mechanism. However, we could detect no IGF-1 mRNA expres-
sion using firstly Northern blot analysis or the more sensitive RT-
PCR method. In fact, IGF-1 mRNA has not been detected using
RT-PCR in a large number of breast cancer cell lines (Quinn et al,
1996), although IGF-2 mRNA has been detected both in T47D
cells and late passage MCF 7 cells (Yee et al, 1988). Using RT-
PCR, we demonstrated that both of our subclones expressed IGF-2
mRNA and we were able to identify a significant, E2-induced
increase in IGF-2 expression primarily in the MCF 7/5–23 cells
(Figure 4). Thus, IGF-2, a ligand that has a moderately high
affinity for the IGF-1R, may act as an autocrine regulator of cell
growth in these cell lines but we have not as yet demonstrated the
presence of immunoreactive IGF-2. This may be especially
important for the MCF 7/5–23 cells, which we have shown are
responsive to IGF-1 and express IGF-1R that is up-regulated by
physiological concentrations of E2. Interestingly, immunoreactive
IGF-2 activity has been detected in MCF 7 (Lee et al, 1994a) and
T47D cells (Osborne et al, 1989) and in a tamoxifen-resistant MCF
7 subclone (Lee et al, 1994b) developed by Toi et al (1993).
Finally, in MCF 7/5–23 cells the up-regulation of IGF-1R
expression by E2 only partially inhibited by tamoxifen combined
with the sensitivity of these cells to IGF-1, may be the explanation
for the relative tamoxifen-resistance of MCF 7/5–23 cells
compared to MCF 7/5–21 cells which are unable to bypass growth
inhibition by tamoxifen through the IGF-1R pathway.
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